electroCore Publishes Study on TAC-STIM Device Enhancing Performance in Military Training
electroCore announced the publication of a peer reviewed paper titled "Non-Invasive Transcutaneous Vagal Nerve Stimulation Enhances Mood, Task Performance, and Learning in a High-Stress Military Training Environment" which will be presented at the Applied Human Factors and Ergonomics Conference on December 8, 2025. The paper presents results from the latest controlled study involving the Company's proprietary TAC-STIM non-invasive transcutaneous vagal nerve stimulation, tVNS, device, which confirm the ability of the TAC-STIM device to enhance operational performance, resilience, and learning/skill acquisition in high-stress training environments. These findings, the first of their kind conducted in an active-duty operational setting, further position TAC-STIM and related, tVNS/nVNS, devices as transformative solutions with compelling potential for military training and deployment, law enforcement organizations, as well as elite athletes and consumers interested in improved cognitive performance and mood.
Get Free Real-Time Notifications for Any Stock
Analyst Views on ECOR
About ECOR
About the author
electroCore (ECOR) Projects 2025 Revenue Between $31.8M and $32M
- Revenue Guidance: electroCore anticipates 2025 revenue between $31.8M and $32M, slightly below the consensus of $31.81M, indicating a cautious outlook on future growth.
- Q4 Growth Projection: The company expects Q4 2025 revenue to be between $9M and $9.2M, representing approximately 30% growth over Q4 2024, suggesting strengthening competitive positioning in the market.
- Cash Position: By the end of 2025, electroCore expects to have approximately $11.6M in cash, down from about $13.2M as of September 30, 2025, reflecting pressure from expansion and investment expenditures.
- Market Reaction: ECOR shares fell 0.62% in premarket trading to $7.0957, indicating investor caution regarding the revenue outlook.
ElectroCore Increases 2025 Revenue Forecast to $32.5M Amid Enhanced Investments and Strategic Growth
Management Strategy: Dr. Thomas Errico highlighted a strategic shift towards growth through targeted investments, acquisitions, and partnerships, focusing on expanding product offerings and enhancing shareholder value while deferring profitability.
Financial Performance: The company reported a record revenue of $8.7 million for Q3 2025, a 33% increase year-over-year, with strong gross margins of 86%, driven by prescription device sales and growth in the VA hospital system.
Outlook and Guidance: CEO Daniel Goldberger raised the full-year revenue guidance to $31.5 million to $32.5 million, projecting a cash balance of approximately $10.5 million by year-end and aiming for positive adjusted EBITDA in the second half of 2026.
Risks and Challenges: Management acknowledged ongoing litigation and the impact of macroeconomic factors on revenue, emphasizing that continued investments in sales and R&D may delay near-term profitability but are essential for long-term growth.
